Recombinant Human Ccl22 protein

Ccl22 (C-C motif chemokine ligand 22), also known as macrophage-derived chemokine (MDC) or STCP-1. is a small secretory protein belonging to the CC chemokine family. It is primarily produced by dendritic cells, macrophages, and certain epithelial cells, playing a pivotal role in immune regulation by mediating leukocyte migration and activation. Ccl22 specifically binds to the CCR4 receptor, which is highly expressed on regulatory T cells (Tregs) and type 2 helper T (Th2) cells. This interaction facilitates the recruitment of these immune cells to inflammatory or tumor microenvironments, contributing to both immune homeostasis and pathological processes like immune evasion in cancer.

Recombinant Ccl22 protein is generated through genetic engineering techniques, typically using bacterial or mammalian expression systems to ensure proper folding and post-translational modifications. The purified protein retains the functional activity of native Ccl22. enabling researchers to study its biological effects in vitro and in vivo. Applications include investigating chemotaxis assays, Treg-mediated immunosuppression, and immune cell signaling pathways. It also serves as a tool to explore therapeutic strategies targeting the Ccl22-CCR4 axis, such as blocking tumor-associated immunosuppression or modulating allergic responses.

In cancer research, elevated Ccl22 levels are linked to poor prognosis, as tumors exploit this chemokine to attract Tregs that suppress anti-tumor immunity. Conversely, in autoimmune or allergic diseases, inhibiting Ccl22 may reduce harmful inflammatory responses. Recombinant Ccl22 thus bridges basic research and translational studies, offering insights into immune modulation and potential therapeutic interventions. Quality control assays, including SDS-PAGE and functional bioactivity tests, ensure batch consistency for experimental reproducibility.